% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Braess:140855,
author = {J. Braess and S. Amler and K.-A. Kreuzer and K. Spiekermann
and H. W. Lindemann and E. Lengfelder and U. Graeven and P.
Staib and W.-D. Ludwig and H. Biersack and Y.-D. Ko and M.
J. Uppenkamp and M. De Wit and S. Korsten and R. Peceny and
T. Gaska and X. Schiel and D. M. Behringer and M. G. Kiehl
and B. Zinngrebe and G. Meckenstock and E. Roemer and D.
Medgenberg and E. Spaeth-Schwalbe and G. Massenkeil and H.
Hindahl and R. Schwerdtfeger and G. Trenn and C. Sauerland
and R. Koch and M. Lablans$^*$ and A. Faldum and D. Görlich
and S. K. Bohlander and S. Schneider and A. Dufour and C.
Buske and M. Fiegl and M. Subklewe and B. Braess and M.
Unterhalt and A. Baumgartner and B. Wörmann and D. Beelen
and W. Hiddemann},
collaboration = {AML-CG},
title = {{S}equential high-dose cytarabine and mitoxantrone
({S}-{HAM}) versus standard double induction in acute
myeloid leukemia-a phase 3 study.},
journal = {Leukemia},
volume = {32},
number = {12},
issn = {1476-5551},
address = {London},
publisher = {Springer Nature},
reportid = {DKFZ-2018-01610},
pages = {2558-2572},
year = {2018},
abstract = {Dose-dense induction with the S-HAM regimen was compared to
standard double induction therapy in adult patients with
newly diagnosed acute myeloid leukemia. Patients were
centrally randomized (1:1) between S-HAM (2nd chemotherapy
cycle starting on day 8 = 'dose-dense') and double
induction with TAD-HAM or HAM(-HAM) (2nd cycle starting on
day 21 = 'standard'). 387 evaluable patients were
randomly assigned to S-HAM (N = 203) and to standard
double induction (N = 184). The primary endpoint overall
response rate (ORR) consisting of complete remission (CR)
and incomplete remission (CRi) was not significantly
different (P = 0.202) between S-HAM $(77\%)$ and double
induction $(72\%).$ The median overall survival was 35
months after S-HAM and 25 months after double induction
(P = 0.323). Duration of critical leukopenia was
significantly reduced after S-HAM (median 29 days) versus
double induction (median 44 days)-P < 0.001. This
translated into a significantly shortened duration of
hospitalization after S-HAM (median 37 days) as compared to
standard induction (median 49 days)-P < 0.001. In
conclusion, dose-dense induction therapy with the S-HAM
regimen shows favorable trends but no significant
differences in ORR and OS compared to standard double
induction. S-HAM significantly shortens critical leukopenia
and the duration of hospitalization by 2 weeks.},
cin = {G230},
ddc = {610},
cid = {I:(DE-He78)G230-20160331},
pnm = {317 - Translational cancer research (POF3-317)},
pid = {G:(DE-HGF)POF3-317},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30275528},
doi = {10.1038/s41375-018-0268-9},
url = {https://inrepo02.dkfz.de/record/140855},
}